Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 With reference to the captioned subject, please find enclosed herewith the intimation dated 26th August, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request/application from the registered shareholder of the Company for issue of Duplicate Share Certificate(s). We request you to kindly take the same on record.
26-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 With reference to the captioned subject, please find enclosed herewith the intimation dated 23rd August, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request(s)/application(s) from the registered shareholder(s) of the Company and/or their legal heir(s) for issue of Duplicate Share Certificate(s). We request you to kindly take the same on record.
23-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 With reference to the captioned matter, please find enclosed herewith the transcript of the Conference Call held on 4th August, 2022. We request you to kindly take the same on record.
10-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 With reference to the captioned subject, please find enclosed herewith the intimation dated 8th August, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request/application from the legal heir(s) of the registered shareholder(s) of the Company for issue of Duplicate Share Certificate(s) for the purpose of claiming those shares from the Investor Education and Protection Fund (IEPF). We request you to kindly take the same on record.
08-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the management of the Company shall be meeting analysts/investors through Pharma Conference hosted by Antique Stock Broking Limited on 10th August, 2022. We request you to kindly take the same on record.
08-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 With reference to the captioned subject, please find enclosed herewith the intimation dated 8th August, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding approval of the request received for issue of Duplicate Share Certificate(s) and issue of letter of confirmation in lieu of the physical share certificate to the registered shareholder(s) in accordance with the provisions of SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated 25th January, 2022. We request you to kindly take the same on record.
08-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 With reference to the captioned subject, please find enclosed herewith the intimation dated 8th August, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request/application from the registered shareholder(s) of the Company for issue of Duplicate Share Certificate(s). We request you to kindly take the same on record.
08-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company's wholly owned subsidiary, Aleor Dermaceuticals Limited has received US Food and Drug Administration (USFDA) Final Approval for Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%. Please find enclosed herewith our press release. We request you to kindly take the same on record.
08-08-2022

Results Earnings Call for Q1FY23 of Alembic Pharmaceuticals

 Conference Call with Alembic Pharmaceuticals Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.
04-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 With reference to the captioned matter, this is to inform the exchange that the audio recording has been hosted on the website of the Company and can be accessed at https://alembicpharmaceuticals.com/quarterly-results/ We request you to kindly take the same on record.
04-08-2022
Next Page
Close

Let's Open Free Demat Account